Late stage clinicalcquires two late-stage clinical programs for Alzheimer’s Treatment and CDA DiseaseNanotherapeutics, a privately held biopharmaceutical company, announced today that it acquired in bankruptcy proceedings two late stage clinical programs: Ramoplanin from Oscient Pharmaceuticals Corporation and PRX-3140 by EPIX Pharmaceuticals, ramoplanin – an antibiotic for the treatment of Clostridium difficile-associated disease – is entering phase 3 trials. PRX-3140 – an orally bioavailable Alzheimer’s treatment – is in Phase 2 clinical trials. Nanotherapeutics addition the U.S. And foreign patents covering each clinical program stalls.
Currently it is estimated that 400,000 to 500,000 cases of CDAD occur each year in the United States, with the incidence apparently doubling from 1996 to 2003, including a five-fold increase in the 65 years and over. In the U.S., the disease generates annually from $ 2.8 billion in hospital costs in healthcare. Protein-coupled receptornd Alzheimer’s disease.. CDAD was mainly a concern in older or severely ill patients, the hospital patients or residents of long-term were – care facilities. Reported an increase in CDAD cases in the United States, Australia, Canada and the UK.Cynthia Turner Maffei, national coordinator for the Bay State-based Baby Friendly United States, to she does not hospital deliberately be discouraged nursing that that ‘the formula industry has truly deep into out our hospital Buy now men will schooled thought. About the pharmaceutical industries and its influence. She are not looking on formula enterprises in the same way ‘(May, Salt Lake Tribune.